{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:56:46Z","timestamp":1788796606013,"version":"build-2803163510"},"reference-count":55,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073767"],"award-info":[{"award-number":["82073767"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273834"],"award-info":[{"award-number":["82273834"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["PAPD2014-65"],"award-info":[{"award-number":["PAPD2014-65"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["82073767"],"award-info":[{"award-number":["82073767"]}],"id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["82273834"],"award-info":[{"award-number":["82273834"]}],"id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012246","name":"Priority Academic Program Development of Jiangsu Higher Education Institutions","doi-asserted-by":"publisher","award":["PAPD2014-65"],"award-info":[{"award-number":["PAPD2014-65"]}],"id":[{"id":"10.13039\/501100012246","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Viruses with rapid replication and easy mutation can become resistant to antiviral drug treatment. With novel viral infections emerging, such as the recent COVID-19 pandemic, novel antiviral therapies are urgently needed. Antiviral proteins, such as interferon, have been used for treating chronic hepatitis C infections for decades. Natural-origin antimicrobial peptides, such as defensins, have also been identified as possessing antiviral activities, including direct antiviral effects and the ability to induce indirect immune responses to viruses. To promote the development of antiviral drugs, we constructed a data repository of antiviral peptides and proteins (DRAVP). The database provides general information, antiviral activity, structure information, physicochemical information, and literature information for peptides and proteins. Because most of the proteins and peptides lack experimentally determined structures, AlphaFold was used to predict each antiviral peptide\u2019s structure. A free website for users (http:\/\/dravp.cpu-bioinfor.org\/, accessed on 30 August 2022) was constructed to facilitate data retrieval and sequence analysis. Additionally, all the data can be accessed from the web interface. The DRAVP database aims to be a useful resource for developing antiviral drugs.<\/jats:p>","DOI":"10.3390\/v15040820","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T04:31:05Z","timestamp":1679632265000},"page":"820","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["DRAVP: A Comprehensive Database of Antiviral Peptides and Proteins"],"prefix":"10.3390","volume":"15","author":[{"given":"Yanchao","family":"Liu","sequence":"first","affiliation":[{"name":"School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youzhuo","family":"Zhu","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Sun","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyue","family":"Ma","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingzhen","family":"Lao","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1810-5842","authenticated-orcid":false,"given":"Heng","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Life Science and Technology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.3201\/eid2313.170727","article-title":"Ebola Response Impact on Public Health Programs, West Africa, 2014\u20132017","volume":"23","author":"Marston","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Pardy, R.D., and Richer, M.J. (2019). Zika Virus Pathogenesis: From Early Case Reports to Epidemics. Viruses, 11.","DOI":"10.3390\/v11100886"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","article-title":"Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003","volume":"362","author":"Zhong","year":"2003","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"The Lancet (2013). MERS-CoV: A global challenge. Lancet, 381, 1960.","DOI":"10.1016\/S0140-6736(13)61184-8"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41392-020-0190-2","article-title":"Overview of lethal human coronaviruses","volume":"5","author":"Chen","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.tips.2013.11.006","article-title":"Current progress in antiviral strategies","volume":"35","author":"Lou","year":"2014","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"170526","DOI":"10.1016\/j.peptides.2021.170526","article-title":"Antiviral peptides against Coronaviridae family: A review","volume":"139","author":"Heydari","year":"2021","journal-title":"Peptides"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10989-020-10072-0","article-title":"Antiviral Peptides: Identification and Validation","volume":"27","author":"Agarwal","year":"2021","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Tonk, M., R\u016f\u017eek, D., and Vilcinskas, A. (2021). Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2. Viruses, 13.","DOI":"10.3390\/v13050912"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.coviro.2011.05.015","article-title":"Contribution of cytokines to pathology and protection in virus infection","volume":"1","author":"Wack","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0163-7258(02)00263-2","article-title":"Pro- and anti-inflammatory cytokines in human immunodeficiency virus infection and acquired immunodeficiency syndrome","volume":"95","author":"Breen","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"ref_12","first-page":"9","article-title":"Cytokines in infection","volume":"48","author":"Pang","year":"1993","journal-title":"Med. J. Malays."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0166-3542(95)06967-4","article-title":"Recombinant superoxide dismutase (SOD) administered by aerosol inhibits respiratory syncytial virus infection in cotton rats","volume":"31","author":"Wyde","year":"1996","journal-title":"Antivir. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/s41590-021-01114-w","article-title":"Recognition and inhibition of SARS-CoV-2 by humoral innate immunity pattern recognition molecules","volume":"23","author":"Stravalaci","year":"2022","journal-title":"Nat. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/17460441.2022.2050693","article-title":"Antimicrobial peptides: A plausible approach for COVID-19 treatment","volume":"17","author":"Rani","year":"2022","journal-title":"Expert. Opin. Drug. Discov."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.3389\/fimmu.2020.02030","article-title":"Antimicrobial Peptides as Potential Antiviral Factors in Insect Antiviral Immune Response","volume":"11","author":"Feng","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"001661","DOI":"10.1099\/jgv.0.001661","article-title":"Natural antimicrobial peptides as a source of new antiviral agents","volume":"102","author":"Zakaryan","year":"2021","journal-title":"J. Gen. Virol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1007\/s00018-019-03138-w","article-title":"Antiviral peptides as promising therapeutic drugs","volume":"76","author":"Campos","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.apsb.2021.07.026","article-title":"A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases","volume":"12","author":"Zhou","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41422-022-00617-x","article-title":"Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant","volume":"32","author":"Xia","year":"2022","journal-title":"Cell Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2165\/00003495-200363240-00005","article-title":"Enfuvirtide","volume":"63","author":"Dando","year":"2003","journal-title":"Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5566","DOI":"10.1080\/07391102.2021.1871958","article-title":"Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: An in silico drug repurposing study","volume":"40","author":"Ahmadi","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1155\/2012\/751057","article-title":"Review of boceprevir and telaprevir for the treatment of chronic hepatitis C","volume":"26","author":"Wilby","year":"2012","journal-title":"Can. J. Gastroenterol."},{"key":"ref_25","first-page":"5","article-title":"Recent Patents and FDA-Approved Drugs Based on Antiviral Peptides and Other Peptide-Related Antivirals","volume":"29","author":"Sardari","year":"2023","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1080\/14787210.2021.1912593","article-title":"Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2","volume":"19","author":"Rostamian","year":"2021","journal-title":"Expert. Rev. Anti Infect. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ali, W., Elsahn, A., Ting, D.S.J., Dua, H.S., and Mohammed, I. (2022). Host Defence Peptides: A Potent Alternative to Combat Antimicrobial Resistance in the Era of the COVID-19 Pandemic. Antibiotics, 11.","DOI":"10.3390\/antibiotics11040475"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1109\/JBHI.2020.2977091","article-title":"DeepAVP: A Dual-Channel Deep Neural Network for Identifying Variable-Length Antiviral Peptides","volume":"24","author":"Li","year":"2020","journal-title":"IEEE J. Biomed. Health Inform."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"bbab263","DOI":"10.1093\/bib\/bbab263","article-title":"AVPIden: A new scheme for identification and functional prediction of antiviral peptides based on machine learning approaches","volume":"22","author":"Pang","year":"2021","journal-title":"Brief. Bioinform."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"D288","DOI":"10.1093\/nar\/gkaa991","article-title":"DBAASP v3: Database of antimicrobial\/cytotoxic activity and structure of peptides as a resource for development of new therapeutics","volume":"49","author":"Pirtskhalava","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"D488","DOI":"10.1093\/nar\/gkab651","article-title":"DRAMP 3.0: An enhanced comprehensive data repository of antimicrobial peptides","volume":"50","author":"Shi","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"D1087","DOI":"10.1093\/nar\/gkv1278","article-title":"APD3: The antimicrobial peptide database as a tool for research and education","volume":"44","author":"Wang","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Qureshi, A., Thakur, N., and Kumar, M. (2013). HIPdb: A database of experimentally validated HIV inhibiting peptides. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054908"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41597-022-01394-3","article-title":"A database of anti-coronavirus peptides","volume":"9","author":"Zhang","year":"2022","journal-title":"Sci. Data"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"D1147","DOI":"10.1093\/nar\/gkt1191","article-title":"AVPdb: A database of experimentally validated antiviral peptides targeting medically important viruses","volume":"42","author":"Qureshi","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"The UniProt Consortium (2021). UniProt: The universal protein knowledgebase in 2021. Nucleic Acids Res., 49, D480\u2013D489.","DOI":"10.1093\/nar\/gkaa1100"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hammami, R., Zouhir, A., Naghmouchi, K., Ben Hamida, J., and Fliss, I. (2008). SciDBMaker: New software for computer-aided design of specialized biological databases. BMC Bioinform., 9.","DOI":"10.1186\/1471-2105-9-121"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/978-1-4939-7000-1_26","article-title":"Protein Data Bank (PDB): The Single Global Macromolecular Structure Archive","volume":"1607","author":"Burley","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"W431","DOI":"10.1093\/nar\/gkab314","article-title":"Mol* Viewer: Modern web app for 3D visualization and analysis of large biomolecular structures","volume":"49","author":"Sehnal","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/381272a0","article-title":"Errors in protein structures","volume":"381","author":"Hooft","year":"1996","journal-title":"Nature"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/BF00228148","article-title":"AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR","volume":"8","author":"Laskowski","year":"1996","journal-title":"J. Biomol. NMR"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Camacho, C., Coulouris, G., Avagyan, V., Ma, N., Papadopoulos, J., Bealer, K., and Madden, T.L. (2009). BLAST+: Architecture and applications. BMC Bioinform., 10.","DOI":"10.1186\/1471-2105-10-421"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"D1388","DOI":"10.1093\/nar\/gkaa971","article-title":"PubChem in 2021: New data content and improved web interfaces","volume":"49","author":"Kim","year":"2021","journal-title":"Nucleic Acids Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: A major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gky1075","article-title":"ChEMBL: Towards direct deposition of bioassay data","volume":"47","author":"Mendez","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.str.2022.11.012","article-title":"Benchmarking AlphaFold2 on peptide structure prediction","volume":"31","author":"McDonald","year":"2023","journal-title":"Structure"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1126\/science.abd9909","article-title":"De novo design of picomolar SARS-CoV-2 miniprotein inhibitors","volume":"370","author":"Cao","year":"2020","journal-title":"Science"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e02312-18","DOI":"10.1128\/JVI.02312-18","article-title":"Design and Characterization of Cholesterylated Peptide HIV-1\/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity","volume":"93","author":"Zhu","year":"2019","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3976","DOI":"10.1038\/s41598-017-04274-8","article-title":"A screen for inhibitory peptides of hepatitis C virus identifies a novel entry inhibitor targeting E1 and E2","volume":"7","author":"Yin","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"12549","DOI":"10.1128\/JVI.01440-10","article-title":"Peptide inhibitors of flavivirus entry derived from the E protein stem","volume":"84","author":"Schmidt","year":"2010","journal-title":"J. Virol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100999","DOI":"10.1016\/j.isci.2020.100999","article-title":"Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection","volume":"23","author":"Yu","year":"2020","journal-title":"iScience"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"199","DOI":"10.7150\/thno.21425","article-title":"Histidine-rich Modification of a Scorpion-derived Peptide Improves Bioavailability and Inhibitory Activity against HSV-1","volume":"8","author":"Zeng","year":"2018","journal-title":"Theranostics"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.antiviral.2005.10.005","article-title":"Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction","volume":"69","author":"Ho","year":"2006","journal-title":"Antivir. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/4\/820\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:01:41Z","timestamp":1760122901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/15\/4\/820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["v15040820"],"URL":"https:\/\/doi.org\/10.3390\/v15040820","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}